Revier Therapeutics Launches with €6M Cardiometabolic Funding
HEIDELBERG, Germany — August 25, 2026 Revier Therapeutics has officially launched operations following the closing of a €6 million...
ASCVD
Advertisement
Cytokinetics Wins UK Approval for MYQORZO in oHCM
SOUTH SAN FRANCISCO, Calif., July 30, 2026 Cytokinetics, Incorporated has achieved a major regulatory and market access milestone for...
Amgen’s Repatha Wins CHMP Support for Broader Heart Protection
THOUSAND OAKS, Calif., July 29, 2026 Amgen has announced that the Committee for Medicinal Products for Human Use (CHMP)...
Novo Nordisk Reports ZEUS Phase 3 Results for Ziltivekimab
BAGSVÆRD, Denmark, July 31, 2026 Novo Nordisk announced headline results from the Phase 3 ZEUS cardiovascular outcomes trial evaluating...
Merck Publishes Science Paper on Scalable Oral PCSK9 Inhibitor Manufacturing
RAHWAY, N.J., May 7, 2026 Merck announced the publication of a landmark scientific paper in the journal Science detailing...
Advertisements
BioMarin VOXZOGO Shows Long-Term Growth Benefits
San Rafael, California, United States | May 2, 2026 BioMarin Pharmaceutical Inc. has presented new long-term clinical data for...
Scribe Therapeutics Showcases CRISPR and STX-1150 Data
Alameda, California, United States | April 30, 2026 Scribe Therapeutics has announced significant advancements in its engineered CRISPR gene...
Atom Therapeutics Advances ABP-745 into Phase 2 ASCVD Trial
December 16, 2025 – Cambridge, Massachusetts — Atom Therapeutics has announced the initiation of a multi-regional Phase 2 clinical...
Pulse Biosciences Secures FDA IDE Approval to Launch Clinical Trial of nsPFA Cardiac Surgery System for Atrial Fibrillation
Hayward, CA – September 9, 2025 – Pulse Biosciences, a pioneer in bioelectric medicine and nanosecond pulsed field ablation...
Novartis to Acquire Tourmaline Bio, Expanding ASCVD Pipeline
September 9, 2025 – Basel – In a move set to strengthen its cardiovascular disease portfolio, Novartis announced an...
Advertisement
